Ideas

A2M provided updated FY21e earnings guidance, which projected a slower recovery in 4Q21e than expected and the potential for this to drag into 1Q22e. In light of this we softened the trajectory of the rebound in A2M volumes impacting our SM1 assumptions.

After a year of unprecedented challenges from the coronavirus (COVID-19) spread around the world and large swings in investor sentiment globally, the March 2021 quarter was noteworthy for renewed hope and optimism as the global COVID-19 case rate decreased and viable COVID vaccines began to be rolled out worldwide with bio-medical companies scaling-up production to meet demand.